Chattem/J&J deal closes
This article was originally published in The Tan Sheet
Executive Summary
Chattem announces Jan. 2 it closed its agreement to acquire the U.S. rights to ACT, Unisom, Cortizone, Kaopectate and Balmex brands for $410 mil. in cash. The acquired brands were divested in connection with J&J's acquisition of Pfizer's Consumer Healthcare business (1"The Tan Sheet" Dec. 18, 2006, p. 9 and 2"The Tan Sheet" Oct. 9, 2006, p. 6). "We are very excited to add these leading brands to the company's existing portfolio of quality products," Chattem CEO and Chairman Zan Guerry says. In related news, Standard & Poor's says Chattem will replace Fidelity Bankshares in the S&P SmallCap 600 index after the close of trading Jan. 5...
You may also be interested in...
Chattem Flexes Earnings Guidance After Strong Start For Core Brands
Strong sales in January and high expectations for product initiatives planned for the remainder of the year prompted Chattem to increase its fiscal 2008 earnings estimates, the firm's executives told analysts Jan. 29
Chattem Hopes Brands Acquired From J&J Offset Cool Sales Of Pro-Therapy
For 2007, Chattem expects sales of products recently acquired from Johnson & Johnson to rival its existing "big three," of Gold Bond skin care, Icy Hot topical analgesics and Selsun medicated shampoos
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business